GxPinnacle Logo
Skip to content

What Do Inspectors Check for ICSR Reporting Timelines and Submission?

Pharmacovigilance systems must submit ICSRs within defined regulatory timelines. Regulators expect accurate classification of cases, correct application of reporting timelines, and compliant submission to health authorities.

For: Founders, CEOs & MDs·PV Leads·QA/Compliance·Scientists tasked with documentation

Alignment: Global pharmacovigilance principles (ICH-aligned) and inspection practices

Most useful when: Preparing for inspection, setting up a process, or closing a documentation gap

Key points

  • ICSRs must be reported to regulatory authorities within defined timelines.
  • Cases must be classified correctly to determine reporting requirements.
  • Serious unexpected cases must be reported within expedited timelines.
  • Reporting timelines must be calculated from day zero.
  • Submissions must be accurate, complete, and compliant with regulatory formats.
  • Inspection-ready evidence should demonstrate timely and correct reporting of ICSRs.

What inspectors expect

Each point below should be supported by controlled documents and traceable records.

  • ICSRs must be reported within regulatory timelines.
  • Day zero must be used to calculate reporting deadlines.
  • Case classification must determine reporting requirements.
  • Submission must follow regulatory formats and requirements.
  • Late submissions must be documented and investigated.

Summary

Inspectors assess whether pharmacovigilance systems report ICSRs within required timelines and according to regulatory requirements. They typically review case classification, reporting decisions, submission records, and evidence of compliance with 7-day and 15-day timelines.

Common questions

These are the questions this page is designed to answer directly.

  • What are ICSR reporting timelines?
  • What is the 7-day and 15-day reporting rule?
  • How are pharmacovigilance cases reported?
  • What do inspectors check for ICSR submissions?
  • What are expedited reporting requirements?
  • How are ICSRs submitted to regulators?
  • What triggers expedited reporting?
  • How do inspectors verify reporting timelines?
  • What happens if ICSR reporting is late?
  • What are pharmacovigilance submission requirements?

Evidence objects inspectors expect

ICSR Submission Records

  • E2B submission records
  • CIOMS or MedWatch forms
  • Submission timestamps
  • Acknowledgements from regulatory systems

Reporting Timeline Tracking

  • Calculation of day zero
  • Due date tracking for each case
  • Documentation of reporting timelines
  • Evidence of on-time submission

Case Classification Documentation

  • Serious vs non-serious classification
  • Expected vs unexpected assessment
  • Determination of expedited reporting requirement
  • Documentation supporting classification decisions

Regulatory Submission Systems

  • Safety database submission logs (e.g. Argus)
  • EudraVigilance submissions
  • FDA ESG submissions
  • Local authority reporting confirmations

Regulatory Basis (Primary Sources)

  • GVP Module VI – requirements for ICSR reporting timelines
  • ICH E2D – expedited reporting requirements
  • ICH E2A – clinical trial safety reporting timelines
  • MHRA GPvP guidance – reporting obligations
  • FDA 21 CFR 314.80 and 600.80 – postmarketing reporting timelines

Typical Inspection Questions (What Inspectors Ask)

  • How do you determine reporting timelines?
  • Show me submission records for this case.
  • How do you calculate day zero?
  • What happens if a case is submitted late?
  • How do you ensure compliance with 7-day and 15-day reporting?

Failure patterns

Late submission of ICSRs.

Incorrect classification leading to missed expedited reporting.

Incorrect calculation of day zero.

Missing or incomplete submission records.

Failure to investigate late reporting.

What good looks like

  • Accurate classification of cases for reporting.
  • Correct calculation of reporting timelines.
  • Timely submission of all ICSRs.
  • Complete and traceable submission records.
  • Documented investigation of any late cases.

Operationalisation

  • Define reporting timelines within PV SOPs.
  • Ensure day zero is consistently applied.
  • Implement systems to track submission deadlines.
  • Validate case classification before reporting.
  • Monitor compliance with reporting timelines.
  • Investigate and document any late submissions.

Need regulatory documentation today?

Save time and reduce inspection risk with structured, pre-built process-ready documentation.
Created by industry professionals, adaptable to your organisation.

Related pre-built documentation inside the app

Get AccessLog In

FAQ

What are the 7-day and 15-day reporting rules?

Serious unexpected cases must typically be reported within 15 days, while fatal or life-threatening cases may require reporting within 7 days.

What determines whether an ICSR must be reported within 7 days or 15 days?

Fatal or life-threatening serious unexpected cases must typically be reported within 7 days, while other serious unexpected cases are reported within 15 days. The classification depends on seriousness, expectedness, and regulatory requirements, with timelines calculated from day zero.

What is day zero in reporting timelines?

Day zero is the date when a valid ICSR is first received and triggers regulatory reporting timelines.

What is expedited reporting?

Expedited reporting refers to the rapid submission of serious and unexpected adverse events within defined timelines.

Do inspectors review submission timelines?

Yes. Inspectors frequently review submission records to confirm compliance with reporting timelines.

What happens if reporting is late?

Late reporting may result in inspection findings and requires investigation and CAPA.

How do regulators receive ICSRs?

ICSRs are typically submitted electronically via E2B format through systems such as EudraVigilance or FDA ESG.

Sources

Primary guidance used to inform this map. This page is a structured interpretation layer; always validate against the original source documents.

European Medicines Agency (EMA)

  • Guideline on good pharmacovigilance practices (GVP) – Module VI
    View source

FDA

ICH

MHRA